Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Assets: 2011-2025

Historic Non-Current Assets for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $166.0 million.

  • Adma Biologics' Non-Current Assets rose 129.25% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 129.25%. This contributed to the annual value of $157.3 million for FY2024, which is 117.92% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Non-Current Assets is $166.0 million, which was up 4.54% from $158.8 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non-Current Assets high stood at $166.0 million for Q3 2025, and its period low was $58.4 million during Q1 2021.
  • Over the past 3 years, Adma Biologics' median Non-Current Assets value was $76.7 million (recorded in 2023), while the average stood at $105.6 million.
  • Per our database at Business Quant, Adma Biologics' Non-Current Assets decreased by 7.55% in 2023 and then surged by 129.25% in 2025.
  • Adma Biologics' Non-Current Assets (Quarterly) stood at $67.5 million in 2021, then climbed by 15.60% to $78.1 million in 2022, then dropped by 7.55% to $72.2 million in 2023, then skyrocketed by 117.92% to $157.3 million in 2024, then skyrocketed by 129.25% to $166.0 million in 2025.
  • Its Non-Current Assets stands at $166.0 million for Q3 2025, versus $158.8 million for Q2 2025 and $158.8 million for Q1 2025.